Navigation Links
Oslo and Toulouse Cancer Clusters Join Forces to Drive European Cancer Research Forward
Date:11/13/2008

OSLO, TOULOUSE, France and PARIS, November 13 /PRNewswire/ -- Oslo Cancer Cluster today signed a groundbreaking strategic agreement with the Toulouse Canceropole and Cancer-Bio-Sante Cluster which will lead to an integrated effort to become the leading cancer centers in Europe for developing new cancer therapies. The signatories were Philippe Douste-Blazy, President of Canceropole Toulouse Association, former mayor of Toulouse and former French foreign minister, Jean-Pierre Saintouil, CEO of Toulouse Cancer-Bio-Sante Cluster and Bjarte Reve, CEO of Oslo Cancer Cluster NCE. It also contained an initial series of key initiatives to be implemented over the next two years, including a joint response to the next cancer calls of the EU -Innovative Medicines Initiative.

According to Bjarte Reve, the agreement stems from growing recognition that combined research and industry-based clusters focusing on a particular therapeutic area are the way forward: "Oslo and Toulouse are pioneers in this area. Through partnership between the life science industry, research institutions, university hospitals, government and the Norwegian Cancer Society, we have been able to rapidly develop the Oslo Cancer Cluster. Having developed links with like-minded centres in the US, such as MD Anderson, when we turned to Europe, Toulouse stood out as a potential partner. We are therefore delighted to have signed this agreement and to share our vision of ensuring that patients have access to the latest cancer diagnostics and therapeutics as quickly and cost-effectively as possible."

Philippe Douste-Blazy , initiator of the Toulouse project, congratulated the creators of this collaboration and stressed the similarities between Oslo and Toulouse: "This is especially evident in their ethical approach that cannot be categorized as a purely economic approach but instead places the patient at the heart of the concept."

Jean-Pierre Saintouil, also welcomed the agreement: "Our experience in Toulouse has paralleled that of Oslo. The Canceropole and the Cancer-Bio-Sante Cluster have drawn strength by bringing together a hospital, universities, research institutes and companies and integrating the academic fields and technologies necessary to fight cancer such as biology, chemistry, nanotechnologies, information technologies, mathematics etc., Similar to Oslo, the primary objective is to improve prevention, treatment and diagnostics and thereby the lives of cancer patients."

A POWERFUL COMBINED APPROACH TO IMI PLANNED

Under the terms of the agreement, Oslo Cancer Cluster NCE with Cancer-Bio-Sante Cluster and Toulouse Canceropole commit to cooperate in the fight against cancer, to create new business and industries and to stimulate exchanges and investments, through good practice and effective joint research activities. This will be achieved with the cooperation of industry, academia, training, finance & venture capital and government in the respective regions. Both parties are also committed to putting physical resources in place - Oslo recently announced a Euro 150 million investment in a Cancer Innovation Park to be completed by august 2012, while Toulouse is building the Canceropole and numerous other dedicated facilities at a cost of Euros I billion.

New thinking is a major feature of both projects, the Cancer Innovation Park in Oslo will include a high school and dedicated phase 1 clinical trials unit, while Canceropole has a multidisciplinary life sciences institute and business centre, a hospital dedicated to innovation close to important research centers (Pierre Fabre and Sanofi Aventis.)

Moving forward, a series of potential initiatives have already been identified:

- Exchanging knowledge, scientific, technological and market

intelligence,

- Exchanging qualified staff (post docs),

- Sharing access to research and testing facilities,

- Developing new and better services to clustered firms

- Exchanging best practices in all fields from project management

for site development (Toulouse Cancer Campus and Oslo Cancer Cluster

Innovation Park ) to best practices in all the fields around cancer care

and research

- Organizing an annual oncology partnering meeting alternating

between Toulouse and Oslo.

In addition, the new agreement contains an intent to answer the next cancer calls of the EU's Innovative Medicine Initiative: "We believe that by combing our resources and synergizing the SMEs and research labs of both clusters, we will be able to put forward powerful practical proposals to the IMI," concludes Reve.

Interested parties will be able to hear about more about the collaboration at both the upcoming Genesis Conference in London, December 9-10 and at the BIO2009 Convention in Atlanta.

More information:

Bjarte Reve, CEO, Oslo Cancer Cluster NCE - cellphone: +47-971-09-585.

Jean-Pierre Saintouil, CEO, Toulouse Cancer-Bio-Sante Cluster - tel: +33(0)5-34-25-50-43

Cecile Chicoye, Director, Toulouse Canceropole Association - tel +33(0)5-34-25-50-44
For pictures and more information: please visit our websiteS

http://www.oslocancercluster.no/

http://www.canceropole-toulouse.com/

http://www.cancerbiosante.fr/


'/>"/>
SOURCE Oslo Cancer Cluster
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. China Medical Technologies Receives SFDA Approval for Breast Cancer HER-2 FISH Probe
2. Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated
3. Max Planck Institute of Biochemistry Uses MathWorks Tools in Its Quest to Cure Cancer : Institute Accelerates Reconstruction of Key Protein Complexes Using MATLAB and Parallel Computing Toolbox
4. EntreMeds MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial
5. InNexus Biotechnology Announces New EGFR Antibody DXL1218 Targeting Colorectal Cancer and Announces $1.25 Million Private Placement
6. Cancer Care of Western New York Becomes First Center in Western New York to Treat Cancer with RapidArc(TM) Radiotherapy Technology from Varian Medical Systems
7. Study From the University of Texas M.D. Anderson Cancer Center Demonstrates That AHCC(R) is Safe in Combination With Most Chemotherapeutic Agents
8. Bradmer sponsors physician panel to raise awareness of brain cancer treatments
9. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) Centennial Conference
10. AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
11. Data Presented at Cancer Molecular Markers Meeting Suggests Clinical Benefit for Integrating New Molecular Tests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... ... their exceptionally efficient human mesenchymal stem/stromal cell (hMSC) expansion medium. This ... products engineered to radically streamline culture processes, minimize processing time, significantly decrease ...
(Date:12/8/2016)... Dec. 8, 2016  HedgePath Pharmaceuticals, Inc. (OTCQX: ... develops and plans to commercialize innovative therapeutics for ... common stock were approved for trading on the ... on the OTCQX, effective today, under the ticker ... OTCQX market, companies must meet high financial standards, ...
(Date:12/7/2016)... ... 07, 2016 , ... ACEA Biosciences, Inc. presented today updated ... trial for its lead drug candidate, AC0010, at the World Conference on Lung ... determine the safety, antitumor activity, and recommended phase II dosage of AC0010 in ...
(Date:12/7/2016)... Dec. 7, 2016 /PRNewswire/ - Zenith Capital Corp. ("Zenith" or the ... be presented at the Company,s Annual and Special Meeting. ... will take place on Thursday, December 15, 2016 at ... (Room EC1040), 4825 Mount Royal Gate SW, ... notice of meeting and management information circular, containing the matters ...
Breaking Biology Technology:
(Date:12/2/2016)... Dec. 1, 2016   SoftServe , a ... BioLock , an electrocardiogram (ECG) biosensor analysis system ... key IoT asset. The smart system ensures device-to-device ... steering wheel and mobile devices to easily ,recognize, ... As vehicle technology advances, so too must ...
(Date:11/29/2016)... 29, 2016   Neurotechnology , a ... recognition technologies, today released FingerCell 3.0, a ... solutions that run on low-power, low-memory microcontrollers. ... less than 128KB of memory, enabling it ... have limited on-board resources, such as: mobile ...
(Date:11/22/2016)... According to the new market research report "Biometric ... Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact and Non-contact), Application, ... is expected to grow from USD 10.74 Billion in 2015 to reach ... and 2022. Continue Reading ... ...
Breaking Biology News(10 mins):